31 January 2023 in Statistics in Medicine
Intensity‐based multistate models provide a useful framework for characterizing disease processes, the introduction of interventions, loss to followup, and other complications arising in the conduct of randomized trials studying complex life history processes. Within this framework we discuss the issues involved in the specification of estimands and show the limiting values of common estimators of marginal process features based on cumulative incidence function regression models. When intercurrent events arise we stress the need to carefully define the target estimand and the importance of avoiding targets of inference that are not interpretable in the real world. This has implications for analyses, but also the design of clinical trials where protocols may help in the interpretation of estimands based on marginal features.
30 September 2022 in Multiple Sclerosis Journal
Background: The current standard endpoint to assess disability accumulation in multiple sclerosis (MS) clinical trials is the time to the first confirmed disability progression, which excludes subsequent progression events. Including recurrent progression events may permit a more comprehensive assessment of treatment effects on disability progression. Objective: To propose a definition of recurrent disability progression events and to compare time-to-first and recurrent event analysis. Methods: Recurrent disability progression events were defined by expanding the recommended first event definition. Marginal recurrent event methods (negative binomial model, Lin–Wei–Yang–Ying model) were compared with Cox regression in data from three randomized controlled trials in relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS), and in simulated randomized controlled trial data. Results: The recurrent event analyses included a substantially larger number of progression events compared with the time-to-first-event analyses (+7.5% and +9.9% in the RMS trials and +22.7% in the PPMS trial). The increase in the number of events resulted in more precise treatment effect estimates and a corresponding gain in statistical power. Conclusion: Our results support the use of recurrent event data analysis, especially in progressive MS trials, to improve estimates of treatment effects, increase statistical power, and better capture the clinically meaningful long-term disability progression experience.
29 October 2024 in Statistics in Medicine
Regression analyses based on transformations of cumulative incidence functions are often adopted when modeling and testing for treatment effects in clinical trial settings involving competing and semi‐competing risks. Common frameworks include the Fine–Gray model and models based on direct binomial regression. Using large sample theory we derive the limiting values of treatment effect estimators based on such models when the data are generated according to multiplicative intensity‐based models, and show that the estimand is sensitive to several process features. The rejection rates of hypothesis tests based on cumulative incidence function regression models are also examined for null hypotheses of different types, based on which a robustness property is established. In such settings supportive secondary analyses of treatment effects are essential to ensure a full understanding of the nature of treatment effects. An application to a palliative study of individuals with breast cancer metastatic to bone is provided for illustration.
14 October 2025 in Statistics in Medicine
In complex diseases, individuals are often at risk of several types of possibly semi‐competing events and may experience recurrent symptomatic episodes. This complex disease course makes it challenging to define target estimands for clinical trials. While composite endpoints are routinely adopted, recent innovations involving the win ratio and other methods based on ranking the disease course have received considerable attention. We emphasize the usefulness of multistate models for addressing challenges arising in complex diseases, along with the simplicity and interpretability that come from defining utilities to synthesize evidence of treatment effects on different aspects of the disease process. Robust variance estimation based on the infinitesimal jackknife means that such methods can be used as the basis of primary analyses of clinical trials. We illustrate the use of utilities for the assessment of bleeding outcomes in a trial of cancer patients with thrombocytopenia.